Scarica l'app Stockscreener
6.99
6.68%
-0.50
Dopo l'orario di chiusura:
7.02
0.03
+0.43%
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
Artiva Biotherapeutics, Inc. (ARTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARTV: Phase III NK cell therapy for refractory RA shows high efficacy, safety, and scalable delivery - TradingView
Artiva Biotherapeutics at Stifel forum: nk cell therapy gains traction - Investing.com India
Artiva Biotherapeutics at Stifel forum: nk cell therapy gains traction By Investing.com - Investing.com Canada
Artiva Biotherapeutics Announces Oral Presentation of - GlobeNewswire
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to S&P Global BMI Index - marketscreener.com
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Artiva Biotherapeutics (NASDAQ: ARTV) Grants CEO Aslan Fred 315,000 Derivative Securities and 110,000 Shares - Kalkine Media
Artiva Biotherapeutics (NASDAQ: ARTV) Grants RA Capital Management 16,250 Derivative Securities - Kalkine Media
Artiva Biotherapeutics (NASDAQ: ARTV) Increases 2024 Equity Incentive Plan by Over 5 Million Shares - Kalkine Media
Artiva Biotherapeutics Grants President Miralles Gines Diego 45,000 Shares at No Cost (NASDAQ: ARTV) - Kalkine Media
Director gets 16,250 stock options at $10.42 at Artiva (ARTV) - Stock Titan
Artiva Biotherapeutics CTOO Christopher Horan Granted RSUs and Stock Options - Kalkine Media
Artiva (ARTV) boosts R&D head's stake with 135K new options - Stock Titan
Artiva Biotherapeutics Expands Equity Plan, Elects Directors - TipRanks
Shareholders back more stock awards at Artiva (ARTV) - Stock Titan
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Biotech Keeps Spending in CheckFiscal Year Earnings - careplusvn.com
Artiva Biotherapeutics (ARTV) CEO Fred Aslan Sells 23,429 Shares - GuruFocus
Artiva Biotherapeutics CEO Fred Aslan Executes Sale of 23,429 Shares Under 10b5-1 Plan - Kalkine Media
ARTV: Pivotal phase III trial in refractory RA advances, aiming for first-in-class deep B-cell depletion - TradingView
Artiva Biotherapeutics at cantor healthcare conference: ra push gains ground By Investing.com - Investing.com Canada
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 - TradingView
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® - GlobeNewswire
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - WBOC TV
Artiva Biotherapeutics (ARTV) Dips 0.44% to $11.25, Hovering Near Key SupportWave Equality - careplusvn.com
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressROA Comparison - dars.gov.et
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatConsensus Forecast Report - dars.gov.et
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.63 per ShareLow Growth Earnings - dars.gov.et
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Expense Discipline for Clinical-Stage Developer - careplusvn.com
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):